Adverse Event Reporting and Management

Safety Reporting via EudraVigilance

Posted on digi By digi

EudraVigilance is the European Medicines Agency’s (EMA) centralized database for collecting and analyzing information on adverse events (AEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs). It is the backbone of EU pharmacovigilance, enabling regulators, sponsors, and investigators to detect safety signals and protect trial participants across Europe. Since the implementation of the EU Clinical Trials Regulation (EU-CTR 536/2014), all SUSARs must be submitted electronically via EudraVigilance, making it a mandatory tool for sponsors running trials in the European Union.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

DSUR vs SUSAR Reporting Differences

Posted on digi By digi

In clinical research, Drug Safety Update Reports (DSURs) and Suspected Unexpected Serious Adverse Reaction (SUSAR) reports are critical tools for communicating safety information. Both serve different but complementary functions: SUSARs ensure rapid notification of serious safety concerns, while DSURs provide regulators with an aggregate, annual overview of the evolving safety profile of an investigational product. Together, these reporting requirements form the foundation of global pharmacovigilance, enabling regulators to assess both immediate risks and long-term trends.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

Best Practices in Regulatory Safety Correspondence

Posted on digi By digi

In clinical trials, effective communication with regulators is as important as timely reporting. Regulatory safety correspondence refers to the structured communication that accompanies CIOMS forms, SUSAR reports, and related safety documentation. This correspondence includes cover letters, safety letters to investigators, clarifications requested by authorities, and responses to inspection queries. Done properly, it ensures transparency, builds regulatory confidence, and demonstrates the sponsor’s commitment to patient safety.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)